TNON (43) SNOA (44) WOK (54) NVNO (50) ⌘ Pro Terminal →

Intelligent Bio Solutions Inc. (INBS) — RQD Stock Rating Cockpit

$1.83 +9.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.86

Intelligent Bio Solutions Inc. (INBS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $6.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.86 (+1.53%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-8.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INBS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY INBS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.53-2% Next Q

Q2 (-2Q)

Grade E$1.50+6% Next Q

Q3 (-1Q)

Grade E$1.59+15.1% Next Q

Current

Grade D-$1.83-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INBS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INBS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.88) and Max Pain ($1.92) forces dealer call-delta covering toward $26.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INBS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INBS Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

53.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $1$1.83H: $25

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on INBS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 40.8% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

15/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like INBS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INBS)

✓Walkthrough of INBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.31%⚡ TESTING RESISTANCE

2026-10-30O $1.81H $1.83L $1.69C $1.83VOL 18.2K

RES: $2.07SUP: $1.07SMA50: $1.88SMA200: $3.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INBS Butterfly Map → + Track INBS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INBS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INBS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INBS)

Health Care Rank #732 of 1016 ⚔️ TNON vs INBS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INBS vs. TNON, SNOA, WOK, NVNO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Intelligent Bio Solutions Inc. (INBS) ranks #732 by composite RQD confidence (38/100, grade D-) and #928 by equity capitalization ($6.1M). Within this direct 5-issuer industry benchmark cohort, INBS leads on earnings valuation at N/A trailing P/E, while INBS leads on capital efficiency and profitability with -35.0% ROIC and 40.8% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with INBS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INBS ACTIVE Intelligent Bio Solutions Inc.	D-	38/100	—	40.8%	-35.0%	+9.58%	$6.1M	Benchmark Subject
TNON Tenon Medical Inc.	D-	43/100	—	59.8%	-35.0%	+1.33%	$6.2M	/tnon-vs-inbs →
SNOA Sonoma Pharmaceuticals Inc.	D	44/100	—	38.0%	-35.0%	+5.26%	$5.7M	/snoa-vs-inbs →
WOK WORK Medical Technology Group LTD (Class A)	D+	54/100	—	—	—	-4.35%	$4.9M	/wok-vs-inbs →
NVNO enVVeno Medical Corporation	D	50/100	—	—	-35.0%	+4.08%	$4.9M	/nvno-vs-inbs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001725430

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Intelligent Bio Solutions Inc. (INBS) reported GAAP revenue of $3.1M (-1.9% vs. FY2024 revenue of $3.1M , and +142.9% cumulative change since FY2023) , GAAP net income of -$10.6M, operating cash flow of -$9.7M, and free cash flow of -$9.9M (-1.2% YoY). On the balance sheet, INBS closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$3.1M	-$10.6M	-$9.7M	-$9.9M	$17.7M	—
FY2024 (FY)	2024-06-30	$3.1M	-$10.2M	-$9.6M	-$9.8M	$8.7M	—
FY2023 (FY)	2023-06-30	$1.3M	-$10.6M	-$7.4M	-$7.4M	—	—

3. INBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $1.83 (+9.58% 1D, market cap $6.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INBS ranks #732 in composite RQD confidence.

How does INBS compare to TNON and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), INBS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 40.8%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $6.2M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $5.7M). Among the 5-stock peer group, INBS leads on earnings multiple (N/A) while INBS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INBS?

Per INBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001725430), Intelligent Bio Solutions Inc. generated $3.1M in revenue (-1.9% YoY), -$10.6M in net income, and -$9.9M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INBS trading relative to its 50-day, 200-day, and 52-week technical levels?

INBS last traded at $1.83 (+9.58% on volume of 30,886 shares), positioning the stock -2.66% below its 50-day simple moving average ($1.88) and -42.27% below its 200-day simple moving average ($3.17). Across its 52-week range of $1.35 to $24.90, INBS sits at the 2.0% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.60 to $2.06).

INBS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INBS stock right now?

Intelligent Bio Solutions Inc. (INBS) currently earns a Roarable Rating of D- (Sell — SELL) with 38/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is INBS's 12-month price target and RQD AI Jury consensus?

INBS's 12-month base price target is $1.67 (range $1.3 to $26.14), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INBS RQD Cockpit INBS 12M Forecast INBS Earnings & Move INBS Dividends & DRIP INBS Insiders & 13F INBS Whale Options INBS Profit Sankey INBS News & Why